Decreased circulating and neutrophil mediated VEGF-A165 release in stable long-term cardiac transplant recipients

Table 1 Clinical characteristics of the study population

Clinical variables	CTx recipients ( n = 18)	Healthy controls ( n = 35)
Age (years)	49.6 ± 3.1	49.3 ± 1.6
Male	18 (100%)	16 (46%)
Body mass index (kg/m²)	26.5 ± 0.8
Donor age (years)	24.4 ± 3.2
Time since transplantation (months)	145 ± 20
*Primary diagnosis; n (%)*
CAD	7 (39%)
Cardiomyopathy	9 (50%)
Other	2 (11%)
*Medical conditions post-transplant; n (%)*
Hypertension	12 (67%)
Diabetes mellitus	5 (28%)
Dyslipidemia	11 (61%)
CAV	7 (39%)
*Medications; n (%)*
Statins	17 (94%)
ACEi	5 (28%)
ARBs	7 (39%)
β-blockers	6 (33%)
Calcium channel blockers	14 (78%)
*Immunosuppressive treatments; n (%)*
Cyclosporine A	1 (0.06%)
Tacrolimus	15 (83%)
Sirolimus	3 (17%)
MMF/MPA	13 (72%)
Prednisone
Yes (%)	4 (22%)
No (%)	14 (78%)

ACEi: Angiotensin-converting enzyme inhibitor; ARBs: angiotensin II receptor blockers; CAD: Coronary artery disease, CAV: Cardiac allograft vasculopathy, MMF: Mycophenolate mofetil; MPA: Mycophenolate acid; NYHA: New York heart association. variables are expressed as mean ± SEM and percentages.